Jiangxi Fushine Pharmaceutical Third Quarter 2024 Earnings: CN¥0.092 loss per share (vs CN¥0.04 loss in 3Q 2023)
Jiangxi Fushine Pharmaceutical (SZSE:300497) Third Quarter 2024 Results
Key Financial Results
- Revenue: CN¥294.5m (down 32% from 3Q 2023).
- Net loss: CN¥39.6m (loss widened by 80% from 3Q 2023).
- CN¥0.092 loss per share (further deteriorated from CN¥0.04 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Jiangxi Fushine Pharmaceutical shares are up 13% from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Jiangxi Fushine Pharmaceutical that you should be aware of before investing here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:300497
Jiangxi Fushine Pharmaceutical
Engages in the research, development, manufacture, and sale of APIs and pharmaceutical intermediates in China and internationally.
Mediocre balance sheet and overvalued.
